<DOC>
	<DOCNO>NCT00828503</DOCNO>
	<brief_summary>A prospective , randomized safety efficacy study Certican® add-on therapy CMV disease renal transplant recipient OBJECTIVES : Primary Objective : To demonstrate efficacy Certican® add-on therapy CMV disease comparison either valcyte® ( valganciclovir ) cymevene® ( ganciclovir ) alone , evaluate quantitative measurement CMV-DNA PCR blood ( qCMV-PCR ) Secondary Objectives : To assess safety tolerability Certican® patient CMV- disease To study effect Certican® treatment quality life</brief_summary>
	<brief_title>Certican® ( Everolimus ) Against Cytomegalovirus Disease Renal Transplant Patients</brief_title>
	<detailed_description>DESIGN / PHASE Prospective , single-center , randomize , parallel group , control , phase II study . PATIENTS / GROUPS 40 patient 2 group 20 patient per group Randomization ratio 1:1 , stratification INVESTIGATIONAL DRUG Oral MED 1 : Certican® initial dose : 1,5-3 mg day target trough level : 3-8 ng/mL ( first level perform 3 day adjust - accord judgment clinical investigator - stable degree immunosuppression reach ; thereafter Certican® trough level perform schedule appointment ) COMPARATIVE DRUG No therapy ( add-on design CONCOMITANT MEDICATION Allowed The concomitant immunosuppressive medication adjust additional administration Certican® . For example , patient already receive cyclosporine A tacrolimus , adjust , accord current recommendations4 judgment clinical investigator TOLERABILITY / SAFETY ENDPOINTS : Rejection Hematocrit Platelet count WBC count Wound heal disorder Blood lipid ( cholesterol , triglyceride ) Infections ( CMV ) PHARMACOKINETIC / PHARMACODYNAMIC ENDPOINTS Certican® ( everolimus ) trough level STATISTICAL METHODOLOGY Primary Endpoint : CMV-load ( copies/mL ) Null alternative hypothesis : H0 Treatment Certican® ( everolimus ) combination valcyte® ( valganciclovir ) cymevene® ( ganciclovir ) equal valcyte® ( valganciclovir ) cymevene® ( ganciclovir ) alone reduce CMV-load renal transplant patient CMV-disease H1 : Treatment Certican® ( everolimus ) combination valcyte® ( valganciclovir ) cymevene® ( ganciclovir ) superior valcyte® ( valganciclovir ) cymevene® ( ganciclovir ) reduce CMV load ( copies/mL ) renal transplant patient CMV-disease Type-I -II error - power . α=0.05 ß=0.2 ( power 0.8 ) Statistical methodology ANOVA repeat measure ( CMV-copies/mL ) , one-sided t-test CMV load distinct time-points , one-sided t-test time ( week ) CMV-load reach ≤600 copies/mL Sample size calculation Based one-sided test σ 0.2 relative change CMV-copies , α=0.05 And ß=0.2 sample size 20 patient per group determine . Main analysis set Per-protocol ( efficacy ) intention treat ( ITT ) safety Other endpoint Bonferroni correct t-tests perform CMV-copies/mL time point follow-up period . The time copy ≤ 600 also analyze t-test . All secondary endpoint subgroup analysis perform explorative intention ( descriptive statistic ) .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>CMVdisease renal transplantation , i.e. , ( 1 . ) CMV present blood , ( 2 . ) one follow symptom ( viral syndrome , American Society Transplantation recommendation use clinical trials1 ) : body temperature ≥ 38°C new increase significant malaise leucopenia ( &lt; 3500/mL ) atypical lymphocytosis ≥ 5 % thrombocytopenia ( platelet &lt; 100.000/mL ) cause symptoms/signs identify informed consent patient patient know hypersensitivity everolimus , sirolimus excipients administration strong CYP3A4 Inhibitors ( e.g . ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin ) inducer ( rifampicin ) , unless benefit outweighs risk , accord judgment clinical investigator acute rejection episode first 3 month renal transplantation active hepatitis previous month Significant proteinuria ( &gt; 0.8g/24h Urine ) hepatic impairment , accord criterion define Bénichou et al.2 : singular elevation GPT conjugate bilirubin value twice normal level , combine elevation GOT , AP , total bilirubin , give least one parameter twice normal level hematocrit &lt; 25 % significant wound heal disorder ( anamnestic ) blood white blood cell ( WBC ) count &lt; 3000/mL platelet &lt; 50.000/mL severe dyslipidemia ( cholesterol &gt; 300mg/dL , triglyceride &gt; 350mg/dL ) uncontrolled hypertension ( continuous episode hypertension 140/90 ( WHO classification American Society Transplantation recommendation 3 ) despite adequate hypertensive therapy ) uncontrolled hyperuricemia ( uric acid &gt; 8mg/dL ) pregnancy immunosuppressive protocol allow addition Certican® , accord judgment clinical investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Certi-CMV</keyword>
	<keyword>immunosuppressive switch ( Certican )</keyword>
	<keyword>renal transplant</keyword>
</DOC>